Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical Considerations in the Diagnosis of Viral Respiratory Infections

K. Lynn Cates

Recent advances are allowing the transfer of sensitive and precise rapid viral antigen detection technology from sophisticated research laboratories to standardly equipped clinical diagnostic facilities. It is now possible to identify many viral respiratory pathogens directly from clinical specimens in <1 hr. Rapid antigen detection promises to be of the most value in the identification of respiratory viruses 1) for which antiviral therapy is available, 2) which can be prevented by employing isolation precautions, chemoprophylaxis, and/or immunization, 3) whose presence usually is associated with acute respiratory disease, not just asymptomatic colonization, and 4) which ordinarily are not associated with concomitant bacterial infection, and thus, whose early detection may allow withholding or withdrawing antibiotics. Based on these considerations, the relative usefulness of rapid viral antigen detection of commonly encountered respiratory pathogens will be discussed. In addition, the role of rapid viral detection in diagnosis of respiratory infections in high risk versus otherwise healthy individuals will be explored.

INTRODUCTION

Until recently, laboratory diagnosis of viral respiratory infections was of value primarily as an epidemiologic tool. It rarely was of direct benefit in the management of patients with acute disease because the patients usually were either well or dead before the virus could be identified. Technological advances of the past few years have allowed the transfer of sensitive and specific rapid viral antigen detection methods (Table 1) from sophisticated basic science laboratories to routine diagnostic facilities. It is possible to identify many respiratory viruses directly from clinical samples within 1 day. The development of such rapid viral diagnostic tests is particularly important now that antiviral therapy is becoming available.

Viral antigen detection has several advantages over standard culture and serologic techniques. The most obvious is the availability of the test results early enough so that the patient’s outcome may be improved by appropriate changes in therapy. Because antigen detection does not necessarily require viable organisms, specimen handling requirements are not as stringent as for virus cultures. This broadens the availability of viral diagnostic tests to health care providers who do not have optimal handling, storage, or transport facilities. Antigen detection methods also permit identification of some viruses that are difficult or impossible to cultivate in the laboratory and, occasionally, identification of viruses later in the course of disease, after they

---

From the Department of Pediatrics, Division of Infectious Diseases, University of Connecticut School of Medicine, Farmington, CT.

Address reprint requests to: K. Lynn Cates, M.D., Associate Professor, Department of Pediatrics, Head, Division of Infectious Diseases, University of Connecticut School of Medicine, Farmington, CT 06032.

Received November 19, 1985: accepted November 25, 1985.

© 1986 Elsevier Science Publishing Co., Inc.
52 Vanderbilt Avenue, New York, NY 10017 0732-8893/86/S03.50
are no longer cultivatable. A major advantage of antigen detection over serologic
diagnosis of viral respiratory infections is that no convalescent sample is required.
In addition, not all patients, particularly those who are at the highest risk of serious
respiratory disease (e.g., infants and compromised hosts), are able to mount an an-
tibody response during viral infection (Chanock et al., 1963; Vargosko et al., 1965;
Craft et al., 1979).

Although sensitivity and specificity of antigen detection tests vary from one method
to another, and among different viruses, they often approach, or even surpass, those
of standard culture and serologic techniques. Unprecedented sensitivity and, partic-
ularly, specificity may be possible using monoclonal antibody (Yolken, 1982) and
nucleic acid hybridization techniques (Engleberg and Eisenstein, 1984). Such spec-
ificity will help eliminate the false-positive results caused by nonspecific reactions
with host antigens that were often seen with previous antigen detection techniques.

Each year millions of individuals throughout the world suffer from viral respira-
tory infections. The syndromes listed in Table 2 can be caused by over 200 ser-
ologically distinct viruses. For this reason, close cooperation will be required between
clinicians and virologists if the burgeoning new field of antigen detection is going
to be applied appropriately in the clinical setting. Guidelines must be developed for
choosing which viruses should be sought and which patients should be tested. This
article discusses some of the factors to be considered in determining the value of
antigen detection in the diagnosis of viral respiratory infections from the clinician’s
point of view.

VIRUSES TO BE IDENTIFIED

Availability of Therapeutic and Prophylactic Measures

One of the most important factors to be considered in choosing the viruses to be
sought by antigen detection techniques is the availability of antiviral therapy. Cur-
rently only two drugs are available for use against respiratory viruses, ribavirin for
respiratory syncytial virus (RSV) and amantadine for influenza A infections. Reports

| TABLE 1. Viral Antigen Detection Techniques |
|---------------------------------------------|
| Immunofluorescence                           |
| Radioimmunoassay                             |
| Enzyme immunoassay                           |
| Electron microscopy                          |
| Nucleic acid hybridization                   |

| TABLE 2. Viral Respiratory Infections |
|---------------------------------------|
| Upper respiratory tract              |
| Common cold                          |
| Sinusitis                             |
| Acute otitis media                   |
| Pharyngitis                           |
| Laryngitis                           |
| Laryngotracheobronchitis (croup)      |
| Lower respiratory tract              |
| Pneumonia                            |
| Bronchitis                           |
| Bronchiolitis                        |
on the usefulness of interferon and interferon-inducers in the prevention and therapy of viral respiratory disease have yielded conflicting results and interferon and its inducers currently are available only for limited investigational use (National Institutes of Health, 1979; Hayden and Gwaltney, 1983). Although antigen detection methods have been developed for most of the viruses which are common causes of respiratory infections (Table 3), RSV and influenza A virus will be used as models for discussion since antiviral therapy already is available.

**RESPIRATORY SYNCYTIAL VIRUS**

Respiratory syncytial virus is the most common cause of lower respiratory infections, primarily pneumonia and bronchiolitis, in infants and young children (Hall, 1981a). Repeated infection with RSV is common, but symptoms are milder and usually involve only the upper respiratory tract in older children and adults. Recently, ribavirin has been demonstrated to be effective for RSV disease. Ribavirin (1β-D ribofuranosyl-1,2,4-triazole-3-carboxamide) is a nucleoside that resembles guanosine (Hall et al., 1983a). It is a potent inhibitor of virus replication in vitro. Its spectrum of activity includes RSV, influenza A and B, and parainfluenza viruses. The most effective route of administration is aerosol which is well-tolerated with no significant toxicity. Ribavirin administered by the oral route has marginal, if any, effectiveness (Cohen et al., 1976; Togo et al., 1976).

Ribavirin (Virazole, ICN Pharmaceuticals, Costa Mesa, CA) has been licensed in the United States for RSV infections. In RSV lower respiratory tract infections in infants ribavirin therapy led to significant improvement in arterial oxygen saturation, cough, retractions, rales, and lethargy (Hall et al., 1983; Taber et al., 1983). Ribavirin aerosol treatment also has been demonstrated to be effective in RSV (Hall et al., 1983a), influenza A (Knight et al., 1981; Wilson et al., 1984) and influenza B (McClung et al., 1983) infections in adults. Ribavirin shows potential activity against parainfluenza virus, but no controlled clinical studies have been performed.

Rapid identification of RSV, and perhaps eventually parainfluenza and influenza viruses, will allow early therapy with ribavirin. Positive identification of the organism is important because, although ribavirin is safe, it is quite cumbersome to administer by the aerosol route and it may plug ventilator equipment if therapy is not monitored carefully. Thus, even though it may have a relatively broad-spectrum of activity against respiratory viruses, ribavirin cannot, and should not, be used as empiric therapy for all patients with a possible diagnosis of viral pneumonia.

Nosocomial spread of RSV infections is well-documented (Hall et al., 1975; Downham et al., 1974). Hall et al. (1975a) have shown that, during the months that RSV disease is most prevalent in the community, 45% of infants hospitalized for other
reasons for more than 1 wk, developed nosocomial RSV infections. Ten of 24 staff members also became infected with RSV. Such high rates of spread can be explained, at least in part, by the fact that 92%-100% of infected infants still shed large amounts of virus 7 days into the infection (Hall et al., 1975). Another study demonstrated that there was a very high mortality rate (44%) from nosocomial RSV infections in infants with congenital heart disease (MacDonald et al., 1982). Nursery and pediatric ward outbreaks of severe RSV (Berkovich, 1964), and other respiratory virus infections (Meissner et al., 1984; Downham et al., 1975) also have been reported. Rapid diagnosis of RSV may prove to be useful in reducing transmission of serious respiratory infection by allowing earlier implementation of isolation or cohorting precautions.

**INFLUENZA A VIRUS**

Influenza A virus is a significant cause of morbidity and mortality in adults as well as being an important etiology of serious lower respiratory tract disease in the pediatric population (Douglas and Betts, 1985). It is usually associated with epidemic disease characterized by profound malaise in addition to the more typical respiratory symptoms (i.e., rhinitis, pharyngitis, and cough) seen with the other respiratory viruses.

Amantadine hydrochloride is the only antiviral agent that is currently licensed for treatment of respiratory viruses in the United States. It is a symmetric tricyclic amine that specifically inhibits replication of influenza A viruses. The oral form, Symmetrel (Endo Pharmaceuticals, Wilmington, DE), is licensed for treatment and prevention of influenza A infections. It has little toxicity with short-term (<1 wk) therapy, but has been associated with mild to moderate toxicity of many organ systems, especially the central nervous system, when used for several weeks as is recommended for effective prophylaxis (Dolin et al., 1982). Rimantadine is an analog of amantadine which has similar activity against influenza A, but has less central nervous system toxicity (Dolin et al., 1982). It currently is not licensed for use in the United States.

Treatment with amantadine or rimantidine hydrochloride results in significant clinical improvements in influenza A infections when compared with placebo (Wingfield et al., 1969; Van Voris et al., 1981). Patients treated with either of these drugs have faster resolution of symptoms and are able to resume their normal activities sooner than those treated with placebo. Because influenza A disease is so widespread and so debilitating (Monto and Cavallaro, 1971), early institution of antiviral therapy could have major economic and social impact by decreasing the time lost from work or school for healthy individuals, and by decreasing the mortality rate in those at high risk of severe disease.

It could be argued that all patients with respiratory symptoms during influenza A outbreaks should be treated with amantadine without performing antigen detection testing. However, although during influenza A outbreaks the virus often is the predominant etiology of respiratory symptoms, other potentially treatable organism such as *Mycoplasma pneumoniae*, bacteria, or other viruses also may cause respiratory disease. Thus, many individuals would be treated unnecessarily.

The CDC guidelines for isolation of influenza in adults state that “in the absence of an epidemic, influenza may be difficult to diagnose on clinical grounds and most patients will have fully recovered by the time the laboratory diagnosis is established; therefore, placing all patients with suspect influenza on isolation precautions, although theoretically desirable, is simply not practical in most hospitals” (Garner and Simmons, 1983). By allowing early diagnosis, rapid screening tests may play an
important role in preventing deadly nosocomial outbreaks of influenza infection, particularly in high risk areas of the hospital such as coronary care and intensive care units. In addition, early implementation of isolation precautions may help reduce transmission of influenza to hospital staff.

Early diagnosis of influenza A infections also will allow early institution of amantadine prophylaxis in contacts. Amantadine is not only effective treatment of influenza A infections, but it has been found to be 70%-90% effective in preventing influenza A disease (Cohen et al., 1976; Dolin et al., 1982). Increased utilization of amantadine prophylaxis recently has been proposed by the Immunization Practices Advisory Committee (1985).

Another potential use of antigen detection is for the early recognition of outbreaks of influenza disease in the community, thus allowing for better community health planning. It is likely that confirmation of the presence of virus in the community will stimulate more aggressive implementation of immunization programs than would the mere anticipation of an outbreak. Because influenza may persist in a community from 2 to several weeks, immunization programs can be effective even if they are started after the first cases have been recognized.

Potential to Influence Patient Management

Whether or not antiviral or preventative measures are available, rapid diagnosis promises to help simplify patient care by preventing unnecessary, expensive, and/or invasive diagnostic testing, particularly when the patient presents with atypical symptoms (Dietzman et al., 1976; Kerr et al., 1975). Unlike bacterial and fungal disease, in viral pneumonia and bronchiolitis, usually there is a good correlation between upper and lower respiratory tract cultures. Thus, in many patients, rapid identification of a respiratory virus from a nose or throat specimen will preclude the need to perform invasive diagnostic procedures such as bronchoscopy, transtracheal aspirates, or open lung biopsies. Such procedures should be reserved for patients whose antigen detection tests are negative, or those suspected of having polymicrobial disease.

Under certain circumstances, precise viral diagnosis can help limit antibiotic use. Benefits of restricting antibiotic therapy include decreased incidence of superinfection with fungi and resistant bacteria, as well as a reduction in acute side effects and in sensitization predisposing to future allergic reactions. Rational decisions about limiting antibiotic therapy, however, can only be made based on knowledge of the patterns of colonization and disease caused by individual viruses. One must know if a virus is present, whether it is usually a pathogen, or whether it is just associated with asymptomatic colonization. Data vary with the means of data collection but, generally, RSV (Hall, 1981a), parainfluenza virus (Hall, 1981), and influenza viruses (Cherry, 1973) are found in <1% of normal individuals, and rhinoviruses are found in only ~3% (Cherry 1973). In contrast, because adenovirus may be shed for up to several months after an episode of infection, it has been found in respiratory and fecal samples from <1% to >10% of the population (Van der Veen and Dijkman, 1962; Cherry 1973), and Elveback et al. (1966) reported that the presence of adenovirus was associated with disease in only 49% of individuals. Thus, if RSV, parainfluenza, influenza, or rhinovirus were found in the nasopharynx of a patient with respiratory symptoms, it is highly likely that it is pathogenic. The presence of adenovirus, however, does not necessarily implicate it as an etiologic agent.

Before rapid antigen detection techniques can influence antibiotic use, it also is important to know how often a particular virus is associated with concomitant bacterial infection. Combined bacterial-viral infections have been documented for all
viruses, but are seen much more commonly with some viruses than others. Respiratory syncytial virus and parainfluenza virus infections seldom are accompanied by bacterial superinfections (Elderkin et al., 1965; Hall, 1981; Hall, 1981a). On the other hand, influenza virus infection is regularly followed by secondary bacterial pneumonia (Cherry 1973; Douglas and Betts, 1985). Serious bacterial infections also have been reported with adenovirus infections, particularly in military recruits (Ellenhoffen et al., 1974; Spencer and Cherry, 1981). Thus, a decision to limit antibiotic use is simpler when RSV or parainfluenza viruses, than when influenza or adenoviruses are identified. It is important, however, to remember that in some patients, particularly those who are very seriously ill and those who are in high risk groups, that bacterial or fungal superinfections or polymicrobial infections may be indistinguishable from viral disease alone and, thus, it may not be possible to omit antimicrobial therapy for other organisms simply because a virus has been found.

Another way in which viral antigen detection may aid in management of acute respiratory infections is by enabling the physician to give the patient some idea of the prognosis for the illness. One of the main reasons a patient sees a physician other than for treatment is to find out what to expect from the illness. Giving a specific viral etiology, rather than diagnosing a “viral infection,” serves to enhance the physician’s credibility and reassure the patient, especially if antibiotics are not prescribed.

Table 4 summarizes some of the factors that affect the value of antigen detection for the five most commonly encountered respiratory viruses. First, rapid diagnosis is more important for treatable than nontreatable viruses. Second, the availability of preventative measures such as chemoprophylaxis with amantadine for influenza A, or vaccines for influenza A and B viruses and, in military recruits, for adenoviruses types 4 and 7, helps determine the value of antigen detection for prevention of disease. Whether or not the virus found usually is pathogenic or associated with bacterial superinfection is important. Also, at the present time, rapid viral antigen detection is more important in the diagnosis of severe disease than in such benign conditions as the common cold because early intervention is likely to have a more pronounced effect on morbidity and mortality.

### Table 4. Factors Affecting the Relative Value of Antigen Detection in Viral Respiratory Infections

|                      | RSV | Influenza | Parainfluenza | Adenovirus | Rhinovirus |
|----------------------|-----|-----------|---------------|------------|------------|
| Availability of antiviral therapy | +   | +         | -             | -          | -          |
| Availability of preventative measures | Isolation | +   | +            | +          | +          |
|                      | Prophylaxis | -   | +            | -          | -          |
|                      | Vaccine    | +   | -            | +          | -          |
| Pathogenic if present° | +   | +         | +             | ±          | +          |
| Not often associated with bacterial superinfection | +   | -         | -             | (±)        |
| Frequency of severe disease | + + + | + + + +   | + +          | ±          | -          |

°Prophylaxis with amantadine is available only for influenza A viruses.

°Vaccines are available only for adenoviruses types 4 and 7, and are for use only in military populations.

°Not usually isolated from asymptomatic individuals.
TABLE 5. Groups at High Risk For Severe Viral Respiratory Infections

| Group                                      |
|--------------------------------------------|
| Newborn infants                            |
| Premature infants                          |
| Patients with congenital or acquired immunodeficiency disorders |
| Oncology patients                          |
| Organ transplant recipients                |
| Other patients on immunosuppressive therapy |
| Patients with cardiopulmonary disease      |
| Patients with metabolic disease            |
| The elderly                                |

PATIENTS TO BE TESTED

Patients who are in high risk groups for developing severe viral respiratory infections such as those listed in Table 5 should be the primary candidates for viral antigen detection testing. It should be noted that the size of all of the groups most likely to benefit from early diagnosis of respiratory infections is continually growing due to improved medical care and the resultant increased survival rates.

The present value of antigen detection for viral respiratory infections in normal hosts is limited to management of those with severe disease. However, in the future, if effective antiviral therapy becomes available for routine outpatient use, it is possible that rapid diagnosis will permit early treatment of even mild conditions. Another important potential benefit from rapid diagnosis and early therapy of viral respiratory infections in normal individuals as well as in those at high risk, is a decrease in the incidence of chronic lung disease following lower respiratory infections. It is estimated that a large percentage of chronic lung disease in the United States is caused or exacerbated by viral lower respiratory infection (Kattan et al., 1977; Laraya-Cuasay, 1978; Monto and Ross, 1978; James et al., 1979; Krasinski, 1985).

COMMUNICATION BETWEEN CLINICIANS AND VIROLOGISTS

Once it has been established which patients should be tested, and which viruses should be sought by antigen detection techniques, clinicians and virologists must communicate with each other to insure that proper specimens are collected and that specimen handling is optimal. In addition, they should work together to establish when antigen detection test results should be made available rapidly. If, even though the tests can be run in a very short time, they are run only on certain days, or they are not run until several specimens are batched, results may not be available in time to alter the patient’s course. On the other hand, test results may be generated quickly by the laboratory but not used, either because they do not reach the clinician in a timely fashion, or because the clinician did not intend to act on them anyway.

For antigen detection tests to be of most value for management of acute infections and for preventing nosocomial disease, they need to be simple and inexpensive enough so that they can be performed rapidly as the need arises, optimally even on nights, weekends, and holidays.

PROBLEMS AND LIMITATIONS OF ANTIGEN DETECTION IN VIRAL RESPIRATORY INFECTIONS

The sensitivity and specificity of antigen detection tests for respiratory viruses have already reached, or are rapidly approaching, acceptable levels for clinical use. How-
ever, even with extensive education campaigns to update clinicians on the scope of respiratory viral disease and the indications for ordering viral antigen detection tests, these tests, particularly those employing monoclonal antibodies or nucleic acid hybridization, could potentially be so specific as to be of little practical use. Steps being taken to ensure that the spectrum of antigen detection is not too narrow include employing more than one monoclonal antibody to detect a given virus (Routledge et al., 1985), using monoclonal antibodies in combination with polyclonal antibodies, and developing monoclonal antibodies capable of reacting with a broad range of antigens (Gerhard et al., 1978; Yolken, 1982). The most effective approach to clinical diagnosis will probably prove to be the use of screening panels to test for several of the most common respiratory viruses at once.

Although it is likely that antigen detection will become the standard for diagnosing viral respiratory disease, in some patients viral cultivation will still be needed in order to perform antiviral susceptibility testing. This will be especially important as both antiviral therapy and resistance to antiviral agents become more prevalent. Serology also will be needed in some patients in order to establish clinical significance, since the presence of antigen just like the presence of the virus itself does not necessarily prove it is the cause of the patient's symptoms.

FUTURE CONSIDERATIONS

Now that technology is available to detect viral antigens in <1 hr, what is on the horizon for improved diagnosis of viral respiratory tract disease? First, despite an enormous amount of effort on the parts of countless investigators, there is still no test available that can reliably distinguish between viral and bacterial respiratory infections. Current efforts to help make this distinction include applying some of the same methods employed for viral antigen detection to the detection of substances such as interferon or specific products of viral infection in clinical specimens (Flowers and Scott, 1985). Second, it may be possible to adapt antigen detection technology for use in vivo, perhaps using monoclonal antibodies like radionuclides are used in gallium and technetium scanning. This may permit determination of whether or not a given virus is related to the ongoing disease process. For instance, finding adenovirus antigen in the lung, not just the nasopharynx, of a patient with pneumonia, would provide good evidence that the virus was contributing to the disease process.

CONCLUSION

The use of antigen detection technology for rapid diagnosis of viral respiratory infections promises to be of great value in certain clinical settings. It has the potential to aid in improving morbidity and mortality rates from acute viral respiratory tract disease by permitting earlier institution of antiviral therapy. It also promises to help simplify patient management and to be an important tool to help prevent the spread of viral respiratory infections. In addition, by providing a diagnosis while the physician is still confronted with an acutely ill patient, it will help educate physicians as to the nature of disease caused by specific viruses, and thus, help create the framework for more rational use of antibiotics and antiviral agents. Rapid diagnostic tests also will help teach patients more about viral illness, thus making it easier for them to understand and accept their medical care.

REFERENCES

Berkovich S (1964) Acute respiratory illness in the premature nursery associated with respiratory syncytial virus infections. Pediatrics 34:753.

Chanock RM, Parrott RH, Johnson KM, Kapikian AZ, Bell JA (1963) Myxoviruses: parainfluenza. Am Rev Respir Dis 88(Suppl):152.
Cherry JD (1973) Newer respiratory viruses: their role in respiratory illnesses of children. Adv Pediatr 20:225.

Cohen A, Togo Y, Khakoo R, Waldman R, Siegel M (1976) Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis 133(Suppl):A114.

Craft AW, Reid MM, Gardner PS, Jackson E, Kernahan J, McQuilllin J, Noble TC, Walker W (1979) Virus infections in children with acute lymphoblastic leukemia. Arch Dis Child 54:755.

Dietzman DE, Schaller JC, Ray CG, Reed ME (1976) Acute myositis associated with influenza B infection. Pediatrics 57:255.

Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J (1982) A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 307:580.

Douglas RG, Betts RF (1985) Influenza virus. In Principles and Practices of Infectious Diseases. Eds., GL Mandell, RG Douglas Jr, JE Bennett. New York: John Wiley & Sons, pp 846–866.

Downham MAPS, McQuillin J, Gardner PS (1974) Diagnosis and clinical significance of para-influenza virus infections in children. Arch Dis Child 49:8.

Elderkin FM, Gardner PS, Turk DC, White AC (1965) Aetiology and management of bronchiolitis and pneumonia in childhood. Br Med J 2:722.

Ellenbogen C, Graybill JR, Silva J Jr, Homme PJ (1974) Bacterial pneumonia complicating adenoviral pneumonia. A comparison of respiratory tract bacterial culture sources and effectiveness of chemoprophylaxis against bacterial pneumonia. Am J Med 56:169.

Elverback LR, Fox JP, Kettel A, Brandt CD, Wassermann FE, Hall CE (1966) The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. III. Preliminary report on association of infections with disease. Am J Epidemiol 83:436.

Engleberg NC, Eisenstein BI (1984) The impact of new cloning techniques on the diagnosis and treatment of infectious diseases. N Engl J Med 311:892.

Flowers D, Scott GM (1985) How useful are serum and CSF interferon levels as a rapid diagnostic aid in virus infections? J Med Virol 15:35.

Garner JS, Simmons BP (1983) CDC guidelines for isolation precautions in hospitals. Infect Control 4(Suppl):245.

Gerhard W, Croce CM, Lopes D, Koprowski H (1978) Repertoire of antiviral antibodies expressed by somatic cell hybrids. Proc Natl Acad Sci USA 75:1510.

Hall CB (1981) Parainfluenza viruses. In Textbook of Pediatric Infectious Diseases. Eds., RD Feigin, JD Cherry. Philadelphia: WB Saunders, pp 1235–1247.

Hall CB (1981a) Respiratory syncytial virus. In Textbook of Pediatric Infectious Diseases. Eds., RD Feigin, JD Cherry. Philadelphia: WB Saunders, pp 1247–1267.

Hall CB, Douglas RG Jr, Geiman JM (1975) Quantitative shedding patterns of respiratory syncytial virus in infants. J Infect Dis 132:151.

Hall CB, Douglas RG Jr, Geiman JM, Messner MK (1975a) Nosocomial respiratory syncytial virus infections. N Engl J Med 293:1343.

Hall CB, McBride JT, Walsh EE, Bell DM, Gala GL, Hildreth S, Ten Eyck LG, Hall WJ (1983) Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. N Engl J Med 308:1443.

Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ (1983a) Ribavirin treatment of experimental respiratory syncytial viral infection. JAMA 249:2666.

Hayden FG, Gwaltney JM Jr (1983) Intranasal interferon for prevention of rhinovirus infection and illness. J Infect Dis 148:543.

Horn MEC, Brain E, Gregg I (1975) Respiratory viral infection in childhood. A survey in general practice, Roehampton 1967–1972. J Hyg [Camb] 74:157.

Immunization Practices Advisory Committee (ACIP) (1985) Prevention and control of influenza. MMWR 34:261.

James AG, Lang WR, Liang AY, Mackay RJ, Morris MC, Newman JN, Osborne DR, White PR (1979) Adenovirus type 21 bronchopneumonia in infants and young children. J Pediatr 95:530.
Kattan M, Keens TG, Lapierre J-G, Levison H, Bryan AC, Reilly BJ (1977) Pulmonary function abnormalities in symptom-free children after bronchiolitis. Pediatrics 59:683.

Kerr AA, Downham MAPS, McQuillin J, Gardner PS (1975) Gastric flu. Influenza B causing abdominal symptoms in children. Lancet i:291.

Knight V, Wilson SZ, Quarles JM, Gregg SE, McClung HW, Waters BK, Cameron RW, Zerwas JM, Couch RB (1981) Ribavirin small-particle aerosol treatment of influenza. Lancet ii:945.

Krasinski K (1985) Severe respiratory syncytial virus infection: clinical features, nosocomial acquisition and outcome. Pediatr Infect Dis 4:250.

Laraya-Cuasay LR (1978) Pulmonary sequelae of acute respiratory viral infection. Pediatr Ann 7:42.

MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris Pj, Manning JA (1982) Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 307:397.

McClung HW, Knight V, Gilbert BE, Wilson SZ, Quarles JM, Devine GW (1983) Ribavirin aerosol treatment of influenza B virus infection. JAMA 249:2671.

Meissner HC, Murray SA, Kiernan MA, Snyderman DR, McIntosh K (1984) A simultaneous outbreak of respiratory syncytial virus and parainfluenza virus type 3 in a newborn nursery. J Pediatr 104:680.

Monto AS, Cavallaro JJ (1972) The Tecumseh study of respiratory illness. II. Patterns of occurrence of infection with respiratory pathogens. 1965–1969. Am J Epidemiol 94:280.

Monto AS, Ross HW (1978) The Tecumseh study of respiratory illness. X. Relation of acute infections to smoking, lung function and chronic symptoms. Am J Epidemiol 107:57.

National Institutes of Health (1979) Clinical trials with exogenous interferon: summary of a meeting. J Infect Dis 139:109.

Routledge EG, McQuillin J, Samson ACR, Toms GL (1985) The development of monoclonal antibodies to respiratory syncytial virus and their use in diagnosis by indirect immunofluorescence. J Med Virol 15:305.

Spencer MJ, Cherry JD (1981) Adenoviral infections. In Textbook of Pediatric Infectious Diseases. Eds., RD Feigin, JD Cherry. Philadelphia: WB Saunders, pp 1279–1298.

Taber LH, Knight V, Gilbert BE, McClung HW, Wilson SZ, Norton HJ, Thurson JM, Gordon WH, Atmar RL, Schlaudt WR (1983) Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72:613.

Van der Veen J, Dijkman JH (1962) Association of type 21 adenovirus with acute respiratory illness in military recruits. Am J Hyg 76:149.

Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr (1981) Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 245:1128.

Vargosko AJ, Kim HW, Parrott RH, Jeffries BC, Wong D, Chanock RM (1965) Recovery and identification of adenovirus in infections of infants and children. Bacteriol Rev 29:487.

Wilson SZ, Gilbert BE, Quarles JM, Knight V, McClung HW, Moore RV, Couch RB (1984) Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother 26:200.

Wingfield WL, Pollack D, Grunert RR (1969) Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 281:579.

Yolken RH (1982) Enzyme immunoassays for the detection of infectious antigens in body fluids: current limitations and future prospects. Rev Infect Dis 4:35

DISCUSSION

Professor Habermehl: Do you have any experience with prophylaxis for RSV, particularly within the hospital?

Dr. Cates: Unfortunately, the only agent that's available for RSV infection is ribavirin and it is not effective orally. It can only be used with a very elaborate aerosol mechanism and this just is not practical for preventative measures. Amantadine has no effect against RSV.
**Professor Turano:** Do you have information on prophylaxis of influenza with amantadine?

**Dr. Cates:** Amantadine is very effective in preventing influenza A; however, it has no activity against influenza B. Amantadine and rimantadine have been in widespread use in other parts of the world, particularly Russia. Russia has been using it for a long time, very effectively. In the May 17th issue of the MMWR, there was a very strong statement suggesting much more aggressive use of amantadine both for therapy and prophylaxis of influenza A; however, it still stressed that vaccination was the primary means of prevention. There are two main practical problems with amantadine prophylaxis at a practical level. The first is compliance for up to 8 wk; second, there are side effects, such as nausea and dizziness.